CTI Biopharma CORP Stock: price and insider trades · United States · SEC (Form 4)

About CTI Biopharma CORP

CTI BioPharma Corp. is a US biopharmaceutical company that built its franchise around targeted therapies for blood cancers, with a particular emphasis on myelofibrosis. Historically headquartered in Seattle, Washington, the company developed a profile as a specialist hematology-oncology player rather than a broad-based pharmaceutical group. It was listed in the United States on the Nasdaq market under the ticker CTIC before being acquired by Swedish Orphan Biovitrum AB (Sobi). The acquisition was announced in May 2023 and completed in June 2023, after which CTI BioPharma became an indirect subsidiary of Sobi. That history remains relevant for investors tracking legacy SEC filings and insider transaction activity. ([sec.gov](https://www.sec.gov/Archives/edgar/data/891293/000119312523140076/d436727dex992.htm?utm_source=openai)) The company’s key commercial asset was VONJO® (pacritinib), an oral kinase inhibitor approved by the FDA in the United States for adults with intermediate- or high-risk primary or secondary myelofibrosis and severe thrombocytopenia. This approval was the defining value-creation event in CTI BioPharma’s corporate story, shifting the company from a development-stage biotechnology name to a commercial-stage hematology company. Prior to its acquisition, management’s core focus was on building awareness, physician adoption, and market penetration for VONJO in a highly specialized patient population with limited treatment options. ([sec.gov](https://www.sec.gov/Archives/edgar/data/891293/000089129323000015/ctic-20230331.htm?utm_source=openai)) From a competitive standpoint, CTI BioPharma operated in a narrow but scientifically important niche. In myelofibrosis, treatment selection depends heavily on clinical benefit, tolerability, and the ability to serve patients with significant cytopenias. VONJO’s positioning was designed to address a population that is often underserved by broader therapies, which gave CTI BioPharma a differentiated commercial story even though it remained a relatively small player versus large hematology franchises. The company’s competitive appeal therefore came less from scale and more from asset specificity and clinical need. ([sec.gov](https://www.sec.gov/Archives/edgar/data/891293/000089129323000015/ctic-20230331.htm?utm_source=openai)) Geographically, CTI BioPharma’s operating footprint was centered in the United States. Its corporate base was in Seattle, and its commercial and regulatory execution was primarily tied to the US market. For French, Belgian, and Swiss investors, the key market identifiers are straightforward: the company was US-listed on Nasdaq and domiciled in the United States, with business activities concentrated in US hematology markets before the Sobi transaction. ([sec.gov](https://www.sec.gov/Archives/edgar/data/891293/000089129323000015/ctic-20230331.htm?utm_source=openai)) Recent material developments are dominated by the strategic sale to Sobi, which followed the US launch and commercialization phase of VONJO. As a result, CTI BioPharma is best understood today as a case study in a focused biotech that successfully advanced a single lead asset into the market and then exited via acquisition. For SEO and investor-oriented content, the most relevant themes are its Seattle roots, Nasdaq history, FDA-approved product, specialization in myelofibrosis, and the 2023 acquisition by Sobi. ([sec.gov](https://www.sec.gov/Archives/edgar/data/891293/000119312523140076/d436727dex992.htm?utm_source=openai))